LesenForschungRadarAnlageframework
Anmelden / Registrieren
← Zurück zur Lektüre
NewsThema · 英矽智能Kurzfassung1 Min. LesezeitDisconfirmAI Redaktion

Insilico Medicine Releases Video Introducing Its AI Clinical Trial Prediction System inClinico Agent

Insilico Medicine published a video on its official channel introducing inClinico Agent, an AI agentic system designed to accelerate clinical trial intelligence and predict trial outcomes. This selection recommends the resource for readers interested in AI applications in biopharma to view the product demonstration and official explanation.

2026-10-23 20:41 GMT+8

Insilico Medicine released a video titled "InClinico Agent is Here!" on its official YouTube channel on October 23, 2026. According to the publisher's description, the video introduces the company's newly launched inClinico Agent. This is an AI agentic system designed to accelerate clinical trial intelligence and predict trial outcomes.

For readers focused on specific applications of AI in drug discovery and clinical trials, this video provides a direct official statement regarding the product's functional positioning. While current evidence consists only of the publisher's brief description and does not include independently verified performance data or detailed technical mechanisms, it confirms the company's progress in this specific direction. Professionals in related fields are advised to watch the video for more intuitive product demonstrations and background information.

Quellen

  • youtube.com↗
Thema

英矽智能

英矽智能(Insilico Medicine)作为全球领先的生成式AI驱动生物技术公司,其核心资产Rentosertib(ISM001-055)于2026年9月在中国启动治疗特发性肺纤维化(IPF)的III期临床试验,这是全球首个由AI发现…

Anmelden / Registrieren
LesenForschungRadarAnlageframework

6 Schritte1 BeiträgeAktualisiert 2026-10-24 23:37

Wie es dazu kam

  1. 2022-02-24英矽智能宣布其首款AI发现的抗纤维化药物ISM001-055进入I期临床试验,从靶点发现到临床仅耗时30个月。insilico.com ↗
  2. 2026-01-23英矽智能获美国FDA批准ISM8969(NLRP3抑制剂)的IND申请,拟用于治疗帕金森病。www1.hkexnews.hk ↗
  3. 2026-09-07英矽智能在《自然·生物技术》发表研究,显示Rentosertib在IIa期试验中使患者预测生物年龄显著降低。insilico.com ↗

Was noch ungeklärt ist

  • Rentosertib III期临床试验能否在预计的3-4年内成功获得监管批准?
  • ISM6331在ESMO公布的人体安全性及初步疗效数据是否支持其继续推进至II期?
  • 英矽智能的盈利模式是否可持续依赖于授权交易而非自研药物上市?
Vollständiges Thema lesen →
Recherche fortsetzen →